Influenza A virus H1N1 vaccine - Pfizer

Drug Profile

Influenza A virus H1N1 vaccine - Pfizer

Alternative Names: A/H1N1 influenza virus vaccine - Pfizer; Celvapan A/H1N1 pandemic vaccine - Pfizer; Celvapan H1N1; Inactivated H1N1 pandemic influenza vaccine (whole virion, Vero cell-derived) - Pfizer; Swine flu vaccine - Pfizer

Latest Information Update: 15 Jun 2016

Price : $50

At a glance

  • Originator Baxter International
  • Developer Pfizer
  • Class Influenza A virus H1N1 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza A virus H1N1 subtype

Most Recent Events

  • 03 Jun 2016 Baxalta has been acquired and merged into Shire
  • 01 Dec 2014 Pfizer acquired Baxter International’s marketed vaccines portfolio
  • 02 Aug 2010 Baxter re-initiates a phase I/I trial for Influenza-A virus H1N1 subtype (prevention, in infants, children and adolescents) in Austria and Germany (NCT00976469)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top